HeartBeam Completes Early Enrollment in Heart Attack Detection Pilot Study, Advancing Next-Generation Cardiac Monitoring
HeartBeam, has reached an important milestone in its mission to transform cardiovascular care by completing patient enrollment for its ALIGN-ACS pilot study, which is evaluating the company’s innovative HeartBeam System for the detection of heart attacks. The enrollment was finalized ahead of the company’s previously projected timeline of the third quarter of 2026, highlighting strong operational execution and steady progress toward expanding the clinical capabilities of its proprietary cardiac monitoring platform.
The achievement marks another step forward in HeartBeam’s strategy to bring advanced cardiac diagnostics closer to patients, enabling faster recognition of heart attack symptoms outside traditional healthcare settings. By combining its proprietary three-dimensional electrocardiogram (3D ECG) technology with portable monitoring capabilities, the company aims to help patients receive earlier assessments during cardiac emergencies, potentially reducing treatment delays that often lead to poorer clinical outcomes.
Addressing One of Healthcare’s Most Critical Challenges
Heart disease continues to be the leading cause of death in many countries, including the United States, with heart attacks accounting for hundreds of thousands of deaths each year. Despite ongoing public awareness campaigns, many individuals experiencing symptoms of an acute heart attack delay seeking medical care.
One of the primary reasons for these delays is that heart attack symptoms are frequently misunderstood or dismissed. While severe chest pain is widely recognized as a warning sign, many patients experience more subtle symptoms such as:
- Mild chest discomfort
- Shortness of breath
- Fatigue
- Jaw or neck pain
- Shoulder discomfort
- Nausea
- Sweating
- Indigestion-like sensations
Because these symptoms may initially appear minor or unrelated to a cardiac event, patients often wait several hours before visiting an emergency department.
Research has shown that many patients delay seeking care for more than two hours after symptoms begin. Every minute during this period is critical because heart muscle deprived of blood flow can suffer irreversible damage.
Delayed treatment increases the likelihood of:
- Permanent heart muscle injury
- Heart failure
- Dangerous cardiac complications
- Longer hospital stays
- Higher healthcare costs
- Increased mortality
Reducing the time between symptom onset and medical evaluation remains one of the most important goals in emergency cardiovascular medicine.
Bringing Clinical-Grade Cardiac Assessment to Patients
HeartBeam is developing technology intended to bridge this critical gap between symptom onset and hospital evaluation.
Unlike traditional electrocardiograms performed only in healthcare facilities, the HeartBeam System is designed to allow patients to capture a clinical-grade ECG wherever they are at the moment symptoms occur.
The company’s proprietary 3D ECG technology records cardiac electrical activity using a compact device that can potentially provide physicians with valuable diagnostic information before patients arrive at a hospital.
Rather than relying solely on patients’ descriptions of symptoms, healthcare providers may eventually have access to objective cardiac data recorded during the actual event.
The company’s long-term objective is to shorten the time between symptom recognition and clinical decision-making, ultimately improving patient outcomes through earlier intervention.
Ahead-of-Schedule Enrollment Demonstrates Operational Momentum
The completion of patient enrollment ahead of schedule represents an important operational achievement for HeartBeam.
Clinical studies frequently experience enrollment delays due to challenges such as patient recruitment, site activation, regulatory approvals, or logistical issues.
Successfully completing enrollment earlier than anticipated demonstrates effective coordination among investigators, clinical research teams, participating hospitals, and company leadership.
The milestone also enables HeartBeam to transition sooner into data analysis and preparation for future regulatory discussions.
According to Branislav Vajdic, Ph.D., Founder and President of HeartBeam, completing enrollment ahead of schedule reflects both the quality of the study’s design and the disciplined execution demonstrated by the company’s clinical operations team.
He emphasized that the accomplishment provides a strong foundation as the organization begins planning its future pivotal clinical study.
Supporting Future FDA Discussions
HeartBeam expects data generated from the ALIGN-ACS pilot study to play a central role in upcoming discussions with the U.S. Food and Drug Administration (FDA).
The company is evaluating whether the successful completion of enrollment and the resulting clinical data may support an accelerated pathway toward expanding the regulatory indications for the HeartBeam System.
Currently, the technology is focused on cardiac rhythm assessment.
HeartBeam ultimately hopes to receive FDA clearance allowing the system to assess patients for potential heart attacks as well.
Such an expanded indication would significantly broaden the clinical applications of the company’s platform and increase its value for patients, physicians, and healthcare systems.
Management indicated that complete study findings are expected to be presented later this year following completion of data analysis.
Understanding the ALIGN-ACS Pilot Study
The ALIGN-ACS pilot study was specifically designed to evaluate the HeartBeam System’s ability to assist in identifying acute coronary syndrome (ACS), a medical emergency that includes heart attacks and other serious conditions caused by reduced blood flow to the heart.
The study enrolled 120 patients who presented to emergency departments with chest pain.
Patient recruitment took place across two clinical research sites located in Belgrade, Serbia.
Each participant underwent evaluation using both:
- A conventional 12-lead electrocardiogram (ECG)
- The HeartBeam System utilizing proprietary 3D ECG technology
This study design allows researchers to directly compare the diagnostic performance of the HeartBeam platform against the current clinical standard.
Comparing Diagnostic Accuracy
To ensure scientific rigor, physicians independently evaluated patients using information generated from both ECG approaches.
These findings were then compared with an independently adjudicated clinical diagnosis based on comprehensive patient data, laboratory testing, imaging, physician evaluations, and other diagnostic evidence.
This independently determined diagnosis serves as the study’s “gold standard,” allowing investigators to objectively measure how accurately each ECG approach identifies acute coronary syndrome.
The comparison will help researchers determine whether the HeartBeam System provides clinically meaningful diagnostic information capable of supporting emergency cardiac assessments.
Data Analysis Now Underway
With enrollment complete, HeartBeam has entered the next phase of the clinical program.
Researchers are currently analyzing the collected data to evaluate:
- Diagnostic sensitivity
- Diagnostic specificity
- Agreement with standard ECG findings
- Overall clinical performance
- Potential advantages of the proprietary 3D ECG approach
Following completion of statistical analysis, HeartBeam plans to present the study results at a major cardiology conference later this year.
Presenting findings at leading scientific meetings allows physicians, researchers, and regulatory experts to independently review the data and assess the technology’s clinical value.
Publication of study results may also contribute to broader acceptance within the cardiovascular medicine community.
Preparing for a U.S. Pivotal Clinical Study
The ALIGN-ACS pilot study represents an early but essential step toward a larger pivotal clinical trial planned in the United States.
Pilot studies primarily evaluate feasibility, optimize study design, and generate data that guide larger investigations.
Lessons learned from the current study will help HeartBeam refine important aspects of the upcoming pivotal trial, including:
- Patient selection criteria
- Study endpoints
- Clinical workflow
- Statistical methodologies
- Regulatory expectations
A well-designed pivotal study will ultimately provide the evidence necessary for future FDA review.
Expanding Beyond Arrhythmia Detection
HeartBeam’s regulatory strategy extends beyond its current cardiac monitoring capabilities.
The company intends to seek FDA authorization expanding the HeartBeam System’s indications from cardiac rhythm assessment to include evaluation for heart attack detection.
If successful, this expansion could significantly broaden the technology’s clinical impact.
Patients at elevated cardiovascular risk may eventually be able to record cardiac data immediately after symptoms begin, potentially allowing physicians to identify dangerous cardiac events earlier than would otherwise be possible.
Earlier recognition could help emergency providers determine whether patients require immediate hospitalization, rapid cardiac intervention, or further diagnostic testing.
Building on Previous Scientific Evidence
The ALIGN-ACS study does not represent the company’s first investigation into its proprietary technology.
HeartBeam plans to combine findings from the current pilot study with earlier proof-of-concept research as it prepares for FDA discussions.
Among these supporting studies is research recently published in JACC: Advances, a peer-reviewed cardiovascular journal.
The published research contributes additional scientific evidence supporting the company’s proprietary three-dimensional ECG technology.
Together, prior clinical investigations and the ALIGN-ACS pilot are expected to strengthen HeartBeam’s regulatory submissions while helping define the scope of the future pivotal trial.
Reinforcing the Company’s Long-Term Strategy
The successful completion of enrollment also aligns with HeartBeam’s broader corporate strategy of creating a comprehensive remote cardiac assessment platform.
Rather than focusing solely on traditional ECG monitoring, the company envisions a connected cardiac ecosystem capable of supporting multiple cardiovascular applications.
Potential future capabilities could include:
- Remote heart rhythm monitoring
- Heart attack assessment
- Clinical decision support
- Longitudinal cardiac monitoring
- Integration with telemedicine services
- Improved patient engagement
This platform approach positions HeartBeam to address growing demand for decentralized healthcare solutions that extend advanced diagnostics beyond hospitals and physician offices.
Meeting the Needs of Modern Healthcare
Healthcare systems worldwide continue shifting toward remote patient monitoring, digital diagnostics, and home-based healthcare.
Technological advances are making it increasingly possible for patients to receive sophisticated medical assessments outside traditional clinical environments.
Cardiovascular disease represents one of the most important areas for these innovations because timely diagnosis directly affects patient survival.
Portable diagnostic technologies capable of delivering hospital-quality information remotely may help reduce unnecessary emergency visits while ensuring patients experiencing genuine cardiac emergencies receive immediate medical attention.
HeartBeam’s proprietary platform seeks to contribute to this transformation by bringing advanced ECG capabilities into patients’ hands.
With patient enrollment now complete ahead of schedule, HeartBeam is well positioned to move into the next stages of clinical development.
Data analysis from the ALIGN-ACS pilot study is expected to provide valuable insights into the performance of the company’s proprietary 3D ECG technology while informing the design of its planned U.S. pivotal trial.
The company also anticipates that the study findings will support productive discussions with the FDA regarding an expanded indication for heart attack detection.
As HeartBeam continues advancing its clinical and regulatory programs, the company remains focused on its long-term vision of making rapid, accurate, and accessible cardiac assessment available to patients wherever symptoms occur. By enabling earlier recognition of heart attacks and supporting faster clinical decision-making, the HeartBeam System has the potential to improve emergency cardiac care, reduce treatment delays, and ultimately enhance outcomes for millions of individuals at risk of cardiovascular disease.
Source link: https://www.businesswire.com/
